Cryoablation-Induced Anti-Cancer Immune Reaction
Shinji Osada*, Hisashi Imai, Yoshiyuki Sasaki and Kazuhiro Yoshida
Surgical Oncology, Gifu University School of Medicine, 1-1 Yanagido, Japan

Abstract
Ablative techniques have been developed against advanced liver cancer in cases where surgical resection is impossible. Among the ablation procedures used, thermal ablation therapy is widely applied, and the safety and efficacy of this technique have been well characterized to control local progression of cancer. However, the principle of cryosurgery is not only to control local recurrence, but also to stimulate the immune system into initiating an anti-tumor response. In recent years, we have used a liquid nitrogen-based cryogenic procedure and developed a treatment method for patients with unresectable liver tumors. Following this, repeated treatment was demonstrated to induce anti-cancer immune reaction-related factors. In the present study, a novel strategy of a cryoablation-induced anti-cancer immune reaction will be introduced.

Keywords: Cryoablation; Helper T cell; Immune reaction; Hepatoma; Ablation therapy

Introduction
Hepatic resection has been the only curative option for patients with liver tumors. However, due to limited hepatic reserves, high surgical risk, or unfavorable tumor location, surgery is not always possible [1,2], therefore several ablation techniques, based on chemical (percutaneous ethanol injection), cold-based (cryotherapy), or heat-based (radiofrequency ablation; RFA, microwave coagulation therapy; MCT), have been developed [3]. Among these procedures, thermal ablation therapy [4,5] and cryotherapy [6] have been commonly used in worldwide, and the safety and efficacy of this technique have been well characterized. According to a recent comparative study, while similar success and complication rates were found, local recurrence is more frequent in cryotherapy [7]. However, the principle of cryosurgery is not only to facilitate a low recurrence rate, but also due destruction of tissue intracellular antigens that are released into the circulation enable cryogenic treatment to stimulate the immune system for an anti-tumor response [6,8]. In the present report, a novel strategy with a cryoablation-induced anti-cancer immune reaction will be introduced.

Ablation therapy for local cancer progression
Among several procedures to treat hepatic tumors, RFA is one of the most convenient and reliable regional therapies used to prolong patient survival. A worldwide study demonstrated the complication and mortality rates at 8.9% and 0.5%, respectively [9], and post treatment imaging showed complete avascularity if the tumor diameter was smaller than 3cm [10]. In contrast, the main effect of cryoablation is based on intra and extracellular ice formation and the intracellular ice formation causes injury of intracellular structures, membrane rupture, osmotic dehydration, anoxia and finally cell death [11]. During cryoablation the interface of the frozen/unfrozen liver can be assessed easily with intra-operative ultrasound by the appearance of an echogenic edge with posterior acoustic shadowing, and this is a major advantage of cryoablation over RFA (described later). Morbidity and mortality rates after cryosurgery were demonstrated as being higher than thermal ablation, ranging from 8 to 41% and around 20%, respectively [12]. Among the complications, the phenomenon of cryoshock is responsible for the majority of all mortality. Due to this rare (1%) but severe complication, cryoablation is recognized as a problematic treatment.

Larger tumor size increases the risk of complications and also of local recurrence. In a comparative study, a significantly higher local recurrence rate (38% vs. 17%) was reported for large tumors, diameter over 3cm, but not for small tumor, when RFA was compared with cryo-therapy [7]. Then, RFA is now evaluated as the most favorable procedure among ablation therapies from its safety and certainty, but there are still limits in its usage due to tumor size and location [13].

Significances in immune reaction for cancer progression
Two subtypes of T-helper cells were found to have differences in cytokine secretion pattern and other functions, which indicated that Th1 and Th2 cells were important regulators of immune response. Th1 cells are hypothesized to lead the attack against intracellular pathogens such as viruses, raise the classic delayed-type hypersensitivity skin response to viral and bacterial antigens, and fight cancer cells. Th2 cells are believed to emphasize protection against extracellular pathogens such as multicellular parasites. More recently, a new subset of helper T-cells, called Th17, was reported as being related to the autoimmune diseases [14]. Th1, Th2 and Th17 subsets are produced from a non-committed population of precursor naive T cells (Figure 1). As they attain maturity, Th1 cells also produce IFN-gamma, TNF-alpha, and IL-2. Like the Th1 cells, the emergence of Th2 cells is also dependent on their cytokine environment, such as IL-4 from an APC. In addition, for Th17 cells, IL-6 or TGF-beta is important.

The development of an immune microenvironment for tumor tolerance is achieved through a variety of immune-suppressive mechanisms, and subsequently subverts the immune system away from tumor recognition and rejection [15,16]. During the process of immune suppression, malignant tumor progression can be associated with a general shift in Th1/Th2 immune response; Th1 cytokines are typically lower, while the Th2 marker can be higher or unchanged. Th2 reaction has a variety of suppressive effects for Th1 cytokine production and suppresses killer cells activity. In contrast, IL-12 is another cytokine that can be up-regulated by Th1 activity and subsequently, the Th1/Th2 reaction has a variety of suppressive effects for Th1 cytokine production and suppresses killer cells activity. In contrast, IL-12 is another cytokine that can be up-regulated by Th1 activity and subsequently, the Th1/Th2

*Corresponding author: Shinji Osada, Surgical Oncology, Gifu University School of Medicine, 1-1 Yanagido, Gifu City, 501-1194, Japan, E-mail: shinno@qf-u.ac.jp
Received February 14, 2011; Accepted April 05, 2011; Published April 08, 2011
Copyright: © 2011 Osada S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Novel strategy of cryo-therapy

Unresectable liver tumors were identified at our institute and selected for ultrasound echography-guided percutaneous cryosurgery (PCS) under local anesthesia with a cryoablation system (Mycom cryoneedle; Mayekawa Co. Ltd., Tokyo, Japan). The size of the ice ball was evaluated by intra-operative ultrasound, and freezing was performed for 15 minutes to make a 3-cm ice ball (Figure 2). Three freeze/thaw cycles per tumor were performed per a treatment. Once a week PCS was performed without any other therapy except everyday administration of polysaccharide-K (polysaccharide-Kureha; PSK) on the purpose to produce TNF-alpha [19] and to mediate Th1 dominance [20]. Evaluation of serum factors was performed before and after ablation therapy, and serum tumor markers were measured after every four treatments. Tumors were evaluated by abdominal computed tomography after eight treatments. 22 cases with liver tumor were selected for this treatment (Table 1). For all patients, PCS was performed without any serious complications. In these cases, not only were decreased levels of serum tumor markers measured, but local tumor necrosis was also observed. In addition to local changes of the treated area, tumor necrosis was identified away from the treated area in 5 cases of metastatic tumors, as described in Figure 3.

Serum AA is a major acute-phase protein released into the circulation in response to inflammation [21] and is shown to stimulate the rapid expression of TNF-alpha from cultured neutrophils [22]. Recently, TNF-alpha or IFN-gamma alone was reported to increase significantly the effect of cryo therapy [23], therefore, cryosurgery-induced TNF-alpha expression may have mediated tumor necrosis. In fact for animal models, Th1 cells have been shown to be critical for...
induction of cellular immunity and eradication of the tumor mass [24]. In these particular cases (Figure 4), serum level of AA or CRP was increased after the third treatment, and the serum level of TNF-alpha was increased with keeping low of IL-10. In addition, the Th1/Th2 ratio was clearly increased with repeat treatments. To evaluate the clinical significance of these alterations in serum cytokines, pretreatment levels and maximum levels in response to therapy were compared between the Immune-Reaction (IR) group and Local Effect (LE) group, that simple local change without any extra benefit was noted. Pretreatment levels of IL-10 in the LE group were significantly greater than in the IR group (p = 0.0071), and the maximum value (67.9 ± 6.3 pg/mL) was greater in the LE group than the IR group (38.4 ± 8.1 pg/mL) but no significant difference was found between the two groups. In contrast, both pretreatment levels and maximum levels in response to treatment of TNF-alpha were significantly greater in the IR group than in the LE group. The maximum Th1/Th2 ratio was significantly greater in the IR group than in the LE group, despite the fact that pretreatment levels were similar between the two groups. All these details were described in a previous publication from our department [25].

We can now indicate that induction of immune responses by cryosurgery increases the usefulness of this treatment for unresectable liver tumors. Further studies will assess serum cytokine levels in order to evaluate the timing of PCS as a step-up strategy [26].

**Next step in the development of cryo-surgery**

During the last decade, the development of the procedure focusing on the local control of cancer has brought highly effective instruments. On the other hand, the study of anti-cancer immune reaction has pushed new boundaries that have initiated advancements through several clinical trials. The mechanism is still uncertain, and it is unclear how the anti-cancer immune reaction is associated with cancer broken, but it is clear which factors play critical role. Cryo-surgery including the ability to release anti-cancer proteins might be emphasized to apply the immune therapy, and its possibility will lead brilliant concept, not only for the locally treated tumors, but also at the systemic level as described here, for next decade.

As a conclusion to this review, the next steps will be an exciting action to develop new approaches to blocking cancer with immune reaction theory and provide favorable outcomes for patients with advanced liver cancer.

---

**References**


